Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EpiCept, a New York-based pharmaceutical company involved in the development and commercialization of pharmaceutical products for the treatment of cancer and pain, has announced positive results from a Phase IIb trial evaluating the efficacy and safety of an in-development topical analgesic cream EpiCept NP-1 (NP-1).
Subscribe to our email newsletter
NP-1 contains the FDA-approved drugs amitriptyline and ketamine to relieve pain from various peripheral neuropathies in chemotherapy-induced peripheral neuropathy (CPN).
The Community Clinical Oncology Program funded, multi-center, double-blind, randomized, placebo-controlled study was conducted by the National Cancer Institute (NCI).
The results of the trial demonstrated that the change in average daily neuropathy intensity scores in the NP-1 group achieved a statistically significant reduction in CPN intensity versus placebo.
EpiCept president and CEO Jack Talley said the positive results achieved by NP-1 demonstrate its potential to be a new and effective treatment option for sufferers of CPN.